Outlook for Life Sciences in the US Stock Exchange in 2026: Finding Alpha from Market Errors So far, when the market talks about AI x BioTech, there has not been a real rethinking of the paradigm shift brought about by AI, and a large amount of old cycle experience is still being used to guide the valuation and investment of companies. This is exactly where we can find Alpha. The goal of this article is to discuss where the market may go wrong in 2026. 1、 The transition from "AI drug design" to "physical mechanism+human effect modeling" The current success of AI in drug development mainly focuses on early candidate screening: Molecular generation, target matching, and activity prediction. But what truly determines value is not just whether candidate molecules can be generated, but rather: Can we predict the efficacy and safety in real human bodies. Traditional AI relies on statistical fitting, which fundamentally makes it difficult to handle complex and nonlinear system reactions within the human body. That's also why clinical conversion rates have always been the industry's hard ceiling. The ongoing migration is: AI+biophysical mechanism model+system level simulation. Once the "interpretable mechanism model" is introduced, AI is no longer just a screening tool, but begins to touch the decisive variable of clinical success rate. This may be a real watershed around 2026. Market misjudgment points: Still treating such platforms as' smarter filters' rather than clinical risk pricing tools. 2、 Investment is not the key, compliance is: pricing power comes from 'forced unification' The market generally believes that: The regulation of biomedicine is strict, and AI can only improve efficiency in the early detection stage. But the real impact of AI is not 'faster discovery', but rather: Regulatory agencies have started to only recognize "a certain type of explainable and auditable AI+compliance process". Once this happens, the transmission path will be very cruel: Capital entry → Regulatory requirements for increased interpretability → The compliance process has been systematized The industry is forced to adopt a unified compliance stack → Compliance system gains quasi monopoly pricing power When a platform is designated for internal adoption by FDA/EMA/major pharmaceutical companies, It is no longer SaaS, but a quasi regulatory infrastructure. Market misjudgment points: Underestimating the structural power of the 'compliance interface layer'. 3、 For life sciences, computing power is not the biggest bottleneck, data closure is the key With an understanding of large models, a large number of market investors believe that: AI pharmaceuticals=computing power+big models The more CapEx, the stronger the model, and the higher the success rate But the real bottleneck of biotech may not lie in computing power, but in: Can the experiment generate data consistently and standardly Can clinical and production processes be structured as "learnable objects" The real transmission path is: Computing power → AI assisted experimental services → Standardization of experimental/production operation and maintenance → High quality, traceable data assets → Reverse feeding model → Pricing power shifts from models to data systems That's also why some companies that look like equipment vendors/outsourcing/industrial services, Its economic attribute is switching to AI data infrastructure. 4、 AI is not about saving money, but about 'releasing future cash flows in advance' Old experience suggests that: AI only improves efficiency and reduces costs, so its impact on valuation is limited. But in BioTech, what AI has truly changed is: The distribution of failure rates, not process speed. If AI can significantly improve the success probability of stages II-III, So the posterior probability of future cash flows will be systematically increased. This is not an 'efficiency improvement', but a change in the asset risk pricing model. The typical misjudgment in the market is: Still view AI as an Opex optimization tool, rather than a risk curve reshaping tool. 5、 AI is not replacing clinical practice, but reshaping it Under traditional logic, early clinical assets are systematically discounted due to high failure rates and strong randomness. But the reality change is: AI can identify subgroups of beneficiaries in advance Optimize intermediate indicators and alternative endpoints Improve the probability of capturing real signals This means: 'High failure rate' is no longer equivalent to 'no bet'. Alpha opportunities exist in assets that use AI to reconstruct clinical design and evidence generation pathways, rather than traditional "gambling on luck". 6、 Regulation may slow down AI, but may accelerate differentiation The market often assumes: Long regulatory cycle → AI innovation is difficult to be quickly recognized. But the reality trend is: Regulatory agencies are increasingly focusing on explainable and verifiable AI for Drug Discovery. AI technology that can form consensus during the regulatory consultation stage, Its valuation reassessment often precedes commercialization. Misjudgment lies in: Underestimating the intensity of regulatory demand for 'high-quality evidence generation systems'. 7、 AI enables' drug repositioning 'to achieve economies of scale for the first time Drug repositioning in the old cycle, approaching randomized trials. But AI can: Systematically mining public and private data Quickly build high probability verification paths Form a low-cost, high success rate asset portfolio GLP-1, from diabetes medicine to weight-loss medicine, is a textbook level case in this field. The repositioning of GLP-1 essentially relies on long-term clinical observation rather than AI In the future, such repositioning relying on AI will no longer be a niche strategy, but a replicable asset generation machine. Outlook: The true Alpha comes from where the market may make mistakes The biggest risk of investing in AI driven BioTech is not misreading the technology, but using a framework that has been effective over the past decade to understand an industry that has begun to shift its underlying logic. Not only for life sciences, but almost all industries, in the new year, we may find similar opportunities, huge opportunities!